Zai Lab (NASDAQ:ZLAB) CFO Yajing Chen Sells 1,438 Shares

Key Points

• Yajing Chen, CFO of Zai Lab, sold 1,438 shares of stock for approximately $50,934, reducing their ownership by 7.92% to 16,720 shares valued at $592,222.40.
• Zai Lab reported Q2 earnings of ($0.37) per share on revenue of $109.98 million, missing expectations of $125.66 million.
• Institutional investors hold 41.65% of Zai Lab stock, with significant recent activity including purchases by RTW Investments and Mirae Asset Global Investments.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 1,438 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $35.42, for a total value of $50,933.96. Following the completion of the sale, the chief financial officer owned 16,720 shares in the company, valued at approximately $592,222.40. This represents a 7.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Yajing Chen also recently made the following trade(s):

• On Friday, August 8th, Yajing Chen sold 4,096 shares of Zai Lab stock. The shares were sold at an average price of $34.01, for a total value of $139,304.96.
• On Thursday, June 26th, Yajing Chen sold 2,675 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total value of $96,647.75.
• On Monday, June 2nd, Yajing Chen sold 9,618 shares of Zai Lab stock. The stock was sold at an average price of $30.00, for a total value of $288,540.00.

Zai Lab Price Performance

Shares of ZLAB traded up $1.05 during midday trading on Friday, reaching $35.04. 456,200 shares of the stock were exchanged, compared to its average volume of 653,977. The business's 50-day moving average price is $36.08 and its 200 day moving average price is $33.81. Zai Lab Limited Unsponsored ADR has a twelve month low of $17.50 and a twelve month high of $44.34. The company has a market capitalization of $3.89 billion, a price-to-earnings ratio of -17.18 and a beta of 1.03.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, hitting analysts' consensus estimates of ($0.37). Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%.The business had revenue of $109.98 million for the quarter, compared to analysts' expectations of $125.66 million. Zai Lab has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ZLAB. Wall Street Zen cut Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Citigroup reissued a "buy" rating and set a $69.00 price target (up previously from $66.00) on shares of Zai Lab in a report on Monday, August 11th. Finally, Leerink Partners set a $75.00 price target on Zai Lab and gave the stock an "outperform" rating in a report on Monday, June 30th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.22.

Institutional Investors Weigh In On Zai Lab

A number of institutional investors have recently added to or reduced their stakes in ZLAB. RTW Investments LP purchased a new stake in Zai Lab in the 4th quarter valued at approximately $65,714,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Zai Lab by 46,222.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after purchasing an additional 2,127,598 shares in the last quarter. RA Capital Management L.P. purchased a new stake in Zai Lab in the 4th quarter valued at approximately $33,917,000. Principal Financial Group Inc. boosted its holdings in Zai Lab by 63.6% in the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock valued at $104,257,000 after purchasing an additional 1,121,856 shares in the last quarter. Finally, MPM Bioimpact LLC purchased a new stake in Zai Lab in the 4th quarter valued at approximately $20,952,000. Hedge funds and other institutional investors own 41.65% of the company's stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.